IPOX® CEO Josef Schuster was featured in Nikkei, commenting on SpaceX’s Nasdaq debut and its implications for future large IPOs. Schuster said the strong post-listing performance reflected robust demand and highlighted the depth of U.S. capital markets. The article also cited Jay Ritter, who cautioned that SpaceX’s high price-to-sales ratio and speculative growth areas could create downside risk. Schuster noted that news may drive shares short term, while fundamentals will become more important after earnings reports for investors and markets.

IPOX® Associate Lukas Muehlbauer was cited by Reuters on Kardigan’s planned U.S. IPO, which targets a valuation of up to $1.4 billion and aims to raise as much as $373.3 million. Muehlbauer noted a “clear uptick in biotech IPOs” and said healthcare IPO activity has already surpassed last year’s deal flow, signaling an open window for the sector. He also cautioned that investors remain selective, favoring companies with clinical progress and clearer paths to FDA approval.

IPOX® Associate Muehlbauer was interviewed for ZEIT ONLINE, the digital news platform of the German weekly newspaper DIE ZEIT, on the market impact of major planned IPOs and new share offerings. He discussed SpaceX’s expected $75 billion raise, possible listings from leading AI companies, and the challenge of absorbing significant new equity supply. He also noted that later insider sales may be the more important liquidity test for investors after the initial IPO.

IPOX® Associate Dr. Lukas Muehlbauer was quoted by Reuters on ERock’s NYSE debut after the gas generator maker’s shares opened below their IPO price, valuing the company at $5.49 billion. Muehlbauer said investors were pushing back on valuation amid execution risk, noting that ERock’s growth angle is tied to a substantial backlog from data center power demand, but the market wants proof that backlog can convert into revenue before assigning the company a more premium public-market valuation after its listing.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Parabilis Medicines’ upsized U.S. IPO, which targets a valuation of nearly $2.3 billion as biotech listings regain momentum. Muehlbauer said the larger offering signals a healthier biotech IPO pipeline, while noting investors remain selective and favor larger, better-backed deals. He also highlighted Parabilis’ Regeneron partnership as an external validation of the company’s technology and a source of added credibility ahead of its expected Nasdaq debut under ticker PBLS.

IPOX® CEO Josef Schuster was featured in Reuters’ View article on OpenAI’s confidential U.S. IPO filing, which examined how major AI companies are moving toward public markets. Schuster commented that SpaceX, OpenAI, and Anthropic are seeking public-market capital to finance significant growth, while noting that investors may both reward and punish these companies as their fundamentals develop. He also highlighted that their offering size and initial float could make post-listing trading highly dynamic over time for investors and markets alike.

IPOX® CEO Josef Schuster featured in Japan's largest business paper Nikkei on SpaceX’s planned mega IPO and its potential market impact. The article examines whether an offering of unprecedented scale could temporarily absorb capital, increase stock-specific volatility, and affect index rebalancing, while also attracting new investment over the longer term. Schuster noted that large IPOs can heighten individual-stock volatility and potentially ripple across broader markets, but that investors have limited precedent for an equity debut of this magnitude so far.

IPOX® Research Associate Lukas Muehlbauer commented on Innio’s Nasdaq debut in Reuters coverage of the gas engine maker’s upsized $2.43 billion IPO. Muehlbauer said the market backdrop is supportive for companies building the physical backbone of AI, as investors reward businesses tied to data-center power demand. He noted Innio’s established GE heritage and said the company must show equipment order growth can continue and translate into long-term service revenue for data centers requiring reliable power and maintenance over time globally.

IPOX® VP Kat Liu commented on Quantinuum’s Nasdaq debut in Reuters coverage of the Honeywell-backed quantum computing company’s upsized IPO. Liu said the investment case centers on quantum computing’s long-term role in future infrastructure, supported by its strategic relevance to national security, AI, communications and advanced computing. She also noted Quantinuum’s Honeywell backing and expansion into software, cybersecurity and quantum networking, while cautioning that commercial adoption remains limited and investors remain focused on the sector’s long-term opportunity.

IPOX® VP Kat Liu provided Reuters with market analysis on Anthropic’s confidential U.S. IPO filing, noting that the company is moving to capitalize on strong investor demand for AI and growth stocks while the listing window remains favorable. Reuters reported that Anthropic’s potential IPO could become one of the most consequential market debuts in years, with implications for benchmark indexes, investor flows and how public markets value frontier AI companies alongside SpaceX and OpenAI during a pivotal global listing cycle.

IPOX® Associate Muehlbauer was quoted in Reuters coverage on Quantinuum’s upsized U.S. IPO, which targets a valuation of up to $14.3 billion amid strong investor interest in quantum computing. Muehlbauer said the larger offering suggests robust institutional demand and reflects Quantinuum’s appeal as a scarce strategic asset, while noting that the valuation requires years of successful execution.

Reuters reported that Blackstone-backed Liftoff Mobile is targeting a valuation of up to $3.66 billion in its renewed U.S. IPO, seeking to raise up to $418 million. IPOX® CEO Josef Schuster was quoted on the offering’s market significance, noting that a successful listing could pave the way for similar firms. Schuster also said bullish IPO sentiment may outweigh software valuation concerns tied to AI. Liftoff plans to list on Nasdaq under the ticker “LFTO,” with revised terms for public investors.

IPOX® Associate Lukas Muehlbauer was cited by Bloomberg on Doncasters Group and Innio Holding GmbH’s plans to pursue U.S. listings. Muehlbauer said the companies are aligning their IPOs with key customer bases, citing Doncasters’ North American manufacturing footprint and Innio’s U.S. expansion for data-center gas engines. He noted that while most European firms still list at home, the U.S. remains attractive for select businesses seeking deeper liquidity and alternative regulatory frameworks as they evaluate overseas market opportunities and investor access.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on China’s DSC, which filed for a U.S. IPO after receiving rare regulatory clearance from Chinese authorities despite reporting a nearly 29% revenue decline in 2025. Muehlbauer said DSC is aligning its approval with the strongest U.S. IPO market in years, as sentiment broadens to non-U.S. deals, and noted the approval signals that qualified China-linked companies can still access U.S. markets through its planned Nasdaq listing process.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters in its coverage of WhiteHawk Minerals’ planned U.S. IPO, which targets a valuation of up to $701.2 million. The natural gas royalty firm is seeking to raise up to $187 million and list on the NYSE under “WHK.” Muehlbauer noted strong aftermarket support for AI-adjacent energy businesses, as investor interest in electricity demand and domestic energy assets continues to shape the IPO market across new issue opportunities tied to U.S. power growth.

Reuters highlighted commenty by IPOX® CEO Josef Schuster in its coverage of Safepoint’s planned U.S. IPO, which targets a valuation of up to $1.16 billion and aims to raise as much as $283.3 million. The article framed Safepoint’s NYSE listing within a busy post-Memorial Day IPO market and cited Schuster’s view that the IPOX® 100 U.S. Index’s 16% YTD gain and strong portfolio earnings underscore investor demand for IPOs. Safepoint is expected to list under the symbol SFPT on NYSE.

IPOX® CEO Josef Schuster commented in Reuters on the IPO of Innio, the Advent- and ADIA-backed gas engine manufacturer targeting a valuation of up to $20.25 billion in its planned Nasdaq listing. Schuster noted that investor sentiment remains extremely bullish for IPOs tied to AI and space, citing expectations that these sectors will drive the next wave of global economic growth. He added that pricing sentiment may benefit from strong performance among GE legacy firms, including GE Vernova following spin-offs.

IPOX® Founder Josef Schuster was featured in CNBC coverage of SpaceX’s upcoming IPO, noting IPOX® has “always taken a wait-and-see approach to that market.” He called very low float “a big red flag” and warned, “Anything below 7%, you have to be really careful.” Schuster added investors should avoid “jumping in at this point,” preferring to “let it trade and see” as IPO entry points can become more attractive after initial trading.

IPOX® Associate Muehlbauer was quoted in Reuters coverage of smart ring maker Oura’s confidential U.S. IPO filing, as renewed momentum returns to the new listings market. Muehlbauer said investor appetite for Oura should be decent given recent health-tech listings and renewed buyer interest in companies with repeat revenue and paths to profit. He also highlighted Oura’s partnerships across health, sport, retail and enterprise channels as growth drivers that could strengthen the brand’s defensibility and public-market appeal as it prepares to list publicly.

IPOX® Associate Lukas Muehlbauer was quoted in Reuters coverage of SpaceX’s expected mega IPO and its implications for the broader listings market. Muehlbauer noted that SpaceX’s scale and valuation make it an unusual test case, while investor appetite remains concentrated in companies tied to strong themes such as AI infrastructure, defense, energy, industrials and biotech. He also discussed how issuers may accelerate IPO plans ahead of the anticipated listing.